| Synonym |
| Thai / English name |
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 2.5% (v/v)Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Type of experiment: human liver microsomes Results: grape juice and tea inhibited CYP2C9 activity in vitro.
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14 (M/F=11/3)N(Treatment) : 14 (M/F=11/3)Sex : Both sexAge : 29+/-8 years (range 19-41 years)Route : Oral administrationDose/Conc.(herb) : 8 oz.Duration : -Type of interaction : PharmacokineticsInteraction with drug : FlurbiprofenDose/Conc.(drug) : 100 mgResult : NegativeRemark : Subject: Healthy volunteers received 100 mg flurbiprofen on 5 occasions in a crossover fashion, with at least 1 week separating the 5 trials. Flurbiprofen was preceded in radom sequence by the following: (1) cranberry juice placebo (8 oz.), (2) cranberry juice (8 oz), (3) brewed tea (8 oz), (4) grape juice (8 oz), and (5) fluconazole, a CYP2C9 inhibitor serving as a positive control, with 8 oz of water. Results: none of the 3 beverages (cranberry juice, grape juice and tea) altered CYP2C9-mediated clearance of flurbiprofen in humans.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a recommended daily in take (RDI) 250 mg, this would result in volume per dose index (VDI) of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 4 LDuration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 33.8 +/- 3.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : PositiveRemark : Results: EGCG inhibited serotonin glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 183.6 +/- 29.8 microgram/ml. For a RDI 250 mg, this would result in VDI of 1.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : PositiveRemark : Results: EGCG inhibited serotonin glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 183.6 +/- 29.8 microgram/ml. For a RDI 250 mg, this would result in VDI of 1.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Serotonin*/5-hydroxytryptamine/5-HTDose/Conc.(drug) : 8 mMResult : PositiveRemark : Results: EGCG inhibited serotonin glucoronide (UGT1A6) in human liver microsome with Rough IC50 values of 183.6 +/- 29.8 microgram/ml. For a RDI 250 mg, this would result in VDI of 1.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : Mycophenolic acid*/Mycophenolate/MMF/MPA/MofetilDose/Conc.(drug) : 240 micromolarResult : NegativeRemark : Results: data points did not fit the IC50 curve.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
